Збережено в:
| Автор: | |
|---|---|
| Формат: | Recurso digital |
| Мова: | |
| Опубліковано: |
Zenodo
2026
|
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.5281/zenodo.20123652 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Зміст:
- <p>Lung cancer is presently the leading cause of cancer-related mortality. It is observed worldwide because of its delayed identification, histological heterogeneity, and complex molecular aetiology with significant mutations in EGFR, ALK, KRAS, and TP53.Overall survival rates are still low despite advancements in traditional therapies including radiation, chemotherapy, and surgery, especially in cases of advanced cancer. Precision medicine techniques, such as immunotherapy, photothermal therapy, and molecular targeted therapy, are the focus of emerging therapeutic methods. With its targeted administration, improved bioavailability, controlled release, and less systemic toxicity, nanomedicine has attracted a lot of interest as a flexible platform for treating lung cancer Exosomes, lipid nanoparticles, magnetic nanoparticles, polymeric nanoparticles, Liposomes and PLGA-based nanoparticles are two nanocarriers that have shown encouraging preclinical and clinical results. These approaches enhance anticancer efficacy while minimizing off-target effects by enabling the co-delivery of chemotherapeutics, nucleic acids, and gene-silencing agents. Therapeutic safety and selective targeting are further enhanced by functionalization with tumor-specific ligands and responsive polymers. This review highlights the potential of recent advancements in lung cancer immunotherapy, photothermal therapy, molecular targeted therapy, and nanocarrier-mediated drug delivery to address the shortcomings of conventional approaches and provide customized treatment regimens. Future studies should focus on enhancing nanoparticle design, assessing long-term safety, and translating preclinical results into clinical applications in order to improve patient outcomes.</p>